Oxymetholone

Oxymetholone, is a synthetic anabolic steroid used in the treatment of anemia and for the prophylaxis and treatment of hereditary angioedema.

Oxymetholone is primarily indicated in conditions like Anaemia, Aplastic anemia.

Oxymetholone is contraindicated in conditions like Hypercalcaemia,Breast cancer,Hepatic dysfunction,Hypersensitivity,Prostate cancer.

The severe or irreversible adverse effects of Oxymetholone, which give rise to further complications include Hepatitis, Insomnia, Liver cirrhosis.The symptomatic adverse reactions produced by Oxymetholone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Nausea and vomiting, Acne, Bloating, Clitoral hypertrophy.

Concerns related to adverse effects: • Blood lipid changes: [US Boxed Warning]: Anabolic steroids may cause changes in blood lipids (decreased high density lipoproteins and sometimes increased low density lipoproteins), increasing the risk of arteriosclerosis and coronary artery disease. • Clotting factor alterations: Anabolic steroids may suppress factors II, V, VII, and X; prothrombin time may be increased. • Hepatic effects: [US Boxed Warning]: Androgenic anabolic steroid treatment may cause peliosis hepatis, which occurs when splenic or hepatic tissue is replaced by cysts (blood-filled); may only cause minimal hepatic dysfunction although has been associated with hepatic failure. Androgenic liver cell tumors, which may be benign, although malignant tumors have also been reported; generally regress when anabolic steroid treatment is withdrawn. Both conditions (peliosis and tumors) may not be apparent until liver failure or intra-abdominal hemorrhage develops. Androgen use (low doses) has also been associated with cholestatic hepatitis and jaundice; may be associated with hepatomegaly and right upper-quadrant pain; jaundice is typically reversible upon discontinuation (continuing treatment has been associated with coma and death). Monitor liver function periodically. • Prostate conditions: Androgenic anabolic steroid use may cause prostatic hypertrophy or prostate cancer in elderly men. Disease-related concerns: • Breast cancer: May cause hypercalcemia in women with breast cancer by stimulating osteolysis. • Diabetes: Use with caution in patients with diabetes mellitus; insulin or oral hypoglycemic needs may be altered; monitor carefully. • Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention. Special populations: • Pediatric: May accelerate bone maturation without producing compensatory gain in linear growth in children; effect may continue for 6 months after treatment discontinuation; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers. • Women: Discontinue with evidence of mild virilization in women. Other warnings/precautions: • Appropriate use: Oxymetholone should not replace other anemia treatment supportive measures such as transfusion, correction of iron, folic acid, vitamin B 12 or pyridoxine deficiency, antibacterial therapy, and the appropriate use of corticosteroids.

Concerns related to adverse effects: • Blood lipid changes: [US Boxed Warning]: Anabolic steroids may cause changes in blood lipids (decreased high density lipoproteins and sometimes increased low density lipoproteins), increasing the risk of arteriosclerosis and coronary artery disease. • Clotting factor alterations: Anabolic steroids may suppress factors II, V, VII, and X; prothrombin time may be increased. • Hepatic effects: [US Boxed Warning]: Androgenic anabolic steroid treatment may cause peliosis hepatis, which occurs when splenic or hepatic tissue is replaced by cysts (blood-filled); may only cause minimal hepatic dysfunction although has been associated with hepatic failure. Androgenic liver cell tumors, which may be benign, although malignant tumors have also been reported; generally regress when anabolic steroid treatment is withdrawn. Both conditions (peliosis and tumors) may not be apparent until liver failure or intra-abdominal hemorrhage develops. Androgen use (low doses) has also been associated with cholestatic hepatitis and jaundice; may be associated with hepatomegaly and right upper-quadrant pain; jaundice is typically reversible upon discontinuation (continuing treatment has been associated with coma and death). Monitor liver function periodically. • Prostate conditions: Androgenic anabolic steroid use may cause prostatic hypertrophy or prostate cancer in elderly men. Disease-related concerns: • Breast cancer: May cause hypercalcemia in women with breast cancer by stimulating osteolysis. • Diabetes: Use with caution in patients with diabetes mellitus; insulin or oral hypoglycemic needs may be altered; monitor carefully. • Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention. Special populations: • Pediatric: May accelerate bone maturation without producing compensatory gain in linear growth in children; effect may continue for 6 months after treatment discontinuation; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers. • Women: Discontinue with evidence of mild virilization in women. Other warnings/precautions: • Appropriate use: Oxymetholone should not replace other anemia treatment supportive measures such as transfusion, correction of iron, folic acid, vitamin B 12 or pyridoxine deficiency, antibacterial therapy, and the appropriate use of corticosteroids.

1 to 5 mg/kg (3 (3)) As recommended. PO — Daily. Scraped Dose — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Tablet, Oral: Anadrol-50: 50 mg [scored]

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Agents with Blood Glucose Lowering Effects: Androgens may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Monitor therapy Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Monitor therapy C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. Monitor therapy Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens. Monitor therapy CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). Management: Consider avoiding concomitant use of androgens and cyclosporine. If concomitant use is unavoidable, monitor serum cyclosporine concentrations and for signs and symptoms of hepatotoxicity. Cyclosporine dose reductions may be required. Consider therapy modification Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required. Consider therapy modification

No storage information is recorded for this medicine yet.